Antibacterial Muraymycins from Mutant Strains of Streptomyces sp. NRRL 30471.
Zheng CuiXia-Chang WangStefan KoppermannJon S ThorsonChristian DuchoSteven G Van LanenPublished in: Journal of natural products (2018)
Muraymycins are nucleoside antibiotics isolated from Streptomyces sp. NRRL 30471 and several mutant strains thereof that were generated by random, chemical mutagenesis. Reinvestigation of two mutant strains using new media conditions led to the isolation of three new muraymycin congeners, named B8, B9, and C6 (1-3), as well as a known muraymycin, C1. Structures of the compounds were elucidated by HRMS and 1D and 2D NMR spectroscopic analyses. Complete 2D NMR assignments for the known muraymycin C1 are also provided for the first time. Compounds 1 and 2, which differ from other muraymycins by having an elongated, terminally branched fatty acid side chain, had picomolar IC50 values against Staphylococcus aureus and Aquifex aeolicus MraY and showed good antibacterial activity against S. aureus (MIC = 2 and 6 μg/mL, respectively) and Escherichia coli Δ tolC (MIC = 4 and 2 μg/mL, respectively). Compound 3, which is characterized by an N-acetyl modification of the primary amine of the dissacharide core that is shared among nearly all of the reported muraymycin congeners, greatly reduced its inhibitory and antibacterial activity compared to nonacylated muraymycin C1, which possibly indicates this modification is used for self-resistance.
Keyphrases
- escherichia coli
- high resolution
- staphylococcus aureus
- silver nanoparticles
- wild type
- fatty acid
- magnetic resonance
- biofilm formation
- solid state
- crispr cas
- molecular docking
- klebsiella pneumoniae
- pseudomonas aeruginosa
- methicillin resistant staphylococcus aureus
- wound healing
- multidrug resistant
- cystic fibrosis
- high resolution mass spectrometry